
SPRBD
Healthcare · Biotechnology
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 15, 2025 | Time not confirmed | — | -3.50 | — |
| May 7, 2025 | Time not confirmed | — | -23.96 | — |
| Mar 12, 2025 | Time not confirmed | — | -42.72 | — |
| Nov 11, 2024 | Time not confirmed | — | -15.75 | — |
| Aug 13, 2024 | Time not confirmed | — | -16.73 | — |
| May 14, 2024 | Time not confirmed | — | -21.22 | — |
| Mar 14, 2024 | Time not confirmed | — | -18.19 | — |
| Nov 14, 2023 | Time not confirmed | — | -22.76 | — |
| Aug 15, 2023 | Time not confirmed | — | -23.72 | — |
| May 15, 2023 | Time not confirmed | — | -30.07 | — |
| Mar 17, 2023 | Time not confirmed | — | -35.47 | — |
| Nov 11, 2022 | Time not confirmed | — | -36.29 | — |
| Aug 11, 2022 | Time not confirmed | — | -37.90 | — |
| May 12, 2022 |
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder…
| Time not confirmed |
| — |
| -37.55 |
| — |
| Mar 15, 2022 | Time not confirmed | — | -29.37 | — |
| Nov 16, 2021 | Time not confirmed | — | -36.74 | — |
| Aug 11, 2021 | Time not confirmed | — | -37.85 | — |
| May 13, 2021 | Time not confirmed | — | -31.85 | — |
| Mar 23, 2021 | Time not confirmed | — | -26.88 | — |
| Nov 19, 2020 | Time not confirmed | — | -30.97 | — |